Bausch Health Companies (NYSE:BHC) Issues Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Bausch Health Companies (NYSE:BHC) posted its quarterly earnings results on Wednesday. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44), Zacks reports. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. Bausch Health Companies updated its FY 2025 guidance to EPS.

Bausch Health Companies Price Performance

Shares of BHC stock opened at $6.54 on Thursday. The company has a market cap of $2.37 billion, a PE ratio of -13.63, a price-to-earnings-growth ratio of 0.32 and a beta of 0.68. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The stock’s 50 day simple moving average is $7.37 and its two-hundred day simple moving average is $7.47.

Analysts Set New Price Targets

Several research firms have recently commented on BHC. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Bausch Health Companies has a consensus rating of “Hold” and a consensus target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.